André Planting

3.2k total citations
71 papers, 2.6k citations indexed

About

André Planting is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, André Planting has authored 71 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 29 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in André Planting's work include Cancer therapeutics and mechanisms (24 papers), Cancer Treatment and Pharmacology (17 papers) and Lung Cancer Research Studies (16 papers). André Planting is often cited by papers focused on Cancer therapeutics and mechanisms (24 papers), Cancer Treatment and Pharmacology (17 papers) and Lung Cancer Research Studies (16 papers). André Planting collaborates with scholars based in Netherlands, Belgium and United States. André Planting's co-authors include Jaap Verweij, G. Stoter, Walter J. Loos, Alex Sparreboom, Ate van der Gaast, Maja J.A. de Jonge, Jan H.M. Schellens, Chris Twelves, B Osterwalder and Bruno Reigner and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Analytical Biochemistry.

In The Last Decade

André Planting

70 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
André Planting Netherlands 31 1.6k 923 720 362 196 71 2.6k
L B Grochow United States 32 2.2k 1.4× 1.8k 2.0× 523 0.7× 344 1.0× 276 1.4× 48 3.6k
David A. Van Echo United States 26 1.5k 0.9× 916 1.0× 437 0.6× 322 0.9× 373 1.9× 71 3.0k
Lindsey Gumbrell United Kingdom 17 1.3k 0.8× 932 1.0× 564 0.8× 392 1.1× 549 2.8× 24 2.7k
Ramzi Dagher United States 24 848 0.5× 982 1.1× 656 0.9× 188 0.5× 290 1.5× 39 2.6k
Bert L. Lum United States 38 2.4k 1.5× 1.8k 2.0× 818 1.1× 365 1.0× 291 1.5× 83 4.7k
U. Vanhoefer Germany 29 2.1k 1.3× 967 1.0× 1.2k 1.7× 577 1.6× 193 1.0× 84 3.1k
Ronald G. Stoller United States 27 2.0k 1.3× 920 1.0× 535 0.7× 282 0.8× 268 1.4× 63 3.5k
Yasutsuna Sasaki Japan 35 2.6k 1.6× 1.2k 1.3× 1.2k 1.7× 435 1.2× 455 2.3× 193 4.0k
Steven E. Benner United States 24 1.3k 0.8× 1.1k 1.1× 804 1.1× 378 1.0× 188 1.0× 56 2.9k
Jin S. Lee United States 30 1.2k 0.8× 1.3k 1.5× 960 1.3× 472 1.3× 343 1.8× 60 3.4k

Countries citing papers authored by André Planting

Since Specialization
Citations

This map shows the geographic impact of André Planting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Planting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Planting more than expected).

Fields of papers citing papers by André Planting

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by André Planting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Planting. The network helps show where André Planting may publish in the future.

Co-authorship network of co-authors of André Planting

This figure shows the co-authorship network connecting the top 25 collaborators of André Planting. A scholar is included among the top collaborators of André Planting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with André Planting. André Planting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bol, Jessica M. van der, Ron H.J. Mathijssen, Geert-Jan Creemers, et al.. (2010). A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan. Clinical Cancer Research. 16(2). 736–742. 50 indexed citations
2.
Baird, Richard D., Jos Kitzen, Paul A. Clarke, et al.. (2009). Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Molecular Cancer Therapeutics. 8(6). 1430–1437. 33 indexed citations
3.
Bol, Jessica M. van der, Ron H.J. Mathijssen, Jaco J. Verweij, et al.. (2008). CYP3A phenotype-based individualized dosing of irinotecan to reduce interindividual variability in pharmacokinetics and toxicity: Results from a randomized trial. Journal of Clinical Oncology. 26(15_suppl). 2506–2506. 3 indexed citations
4.
Nuyttens, Joost J., et al.. (2008). Preoperative chemoradiation with capecitabine in locally advanced rectal cancer.. PubMed. 66(2). 71–6. 35 indexed citations
5.
6.
Zuylen, Lia van, John Bridgewater, Alex Sparreboom, et al.. (2004). Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer. Clinical Cancer Research. 10(6). 1949–1955. 16 indexed citations
7.
Planting, André, et al.. (2004). Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer. European Journal of Cancer. 41(1). 93–97. 11 indexed citations
8.
Kruijtzer, C.M.F., Henk Boot, Jos H. Beijnen, et al.. (2003). Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Annals of Oncology. 14(2). 197–204. 37 indexed citations
9.
Jonge, Maja J.A. de, Alex Sparreboom, André Planting, et al.. (2000). Phase I Study of 3-Week Schedule of Irinotecan Combined With Cisplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 18(1). 187–187. 33 indexed citations
10.
Dagnelie, Pieter C., et al.. (1999). Abnormal liver metabolism in cancer patients detected by31P MR spectroscopy. NMR in Biomedicine. 12(8). 535–544. 21 indexed citations
11.
Gerrits, C J, Howard A. Burris, Jan H.M. Schellens, et al.. (1998). Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.. PubMed. 4(5). 1153–8. 34 indexed citations
12.
Sparreboom, Alex, Maja J.A. de Jonge, V van Beurden, et al.. (1997). Pharmacokinetics and oral bioavailability of 9-amino-camptothecin PEG1000 capsules. European Journal of Cancer. 33. S246–S246. 1 indexed citations
13.
Planting, André, M E van der Burg, M de Boer-Dennert, G. Stoter, & Jaap Verweij. (1995). Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors. Annals of Oncology. 6(2). 190–192. 16 indexed citations
14.
Planting, André, S.H. Goey, Martin J. van den Bent, et al.. (1995). Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Annals of Oncology. 6(6). 613–615. 34 indexed citations
15.
Hilkens, P.H.E., André Planting, M.E.L. van der Burg, et al.. (1994). Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. European Journal of Neurology. 1(1). 45–50. 11 indexed citations
16.
Planting, André, G. Stoter, & Jaap Verweij. (1993). Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. European Journal of Cancer. 29(4). 518–519. 61 indexed citations
17.
Gaast, Ate van der, S.C. Henzen‐Logmans, André Planting, G. Stoter, & Jaap Verweij. (1993). Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site. Annals of Oncology. 4(9). 789–790. 5 indexed citations
18.
Verweij, Jaco J., et al.. (1992). Frequent administration of Dabis Maleate, a phase I study. Annals of Oncology. 3(3). 241–242. 3 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L B Grochow Breakdown of academic impact, for papers by David A. Van Echo Breakdown of academic impact, for papers by Lindsey Gumbrell Breakdown of academic impact, for papers by Ramzi Dagher Breakdown of academic impact, for papers by Bert L. Lum Breakdown of academic impact, for papers by U. Vanhoefer Breakdown of academic impact, for papers by Ronald G. Stoller Breakdown of academic impact, for papers by Yasutsuna Sasaki Breakdown of academic impact, for papers by Steven E. Benner Breakdown of academic impact, for papers by Jin S. Lee
Rankless by CCL
2026